{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:47:21Z","timestamp":1791308841787,"version":"4.3.1"},"reference-count":54,"publisher":"American Association for Cancer Research (AACR)","issue":"17","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although the prognosis for clinically localized prostate cancer is now favorable, there are still no curative treatments for castration-resistant prostate cancer (CRPC) and, therefore, it remains fatal. In this study, we investigate a new therapeutic approach for treatment of CRPC, which involves dual targeting of a major signaling pathway that is frequently deregulated in the disease. We found that dual targeting of the Akt and mTOR signaling pathways with their respective inhibitors, MK-2206 and ridaforolimus (MK-8669), is highly effective for inhibiting CRPC in preclinical studies in vivo using a refined genetically engineered mouse model of the disease. The efficacy of the combination treatment contrasts with their limited efficacy as single agents, since delivery of MK-2206 or MK-8669 individually had a modest impact in vivo on the overall tumor phenotype. In human prostate cancer cell lines, although not in the mouse model, the synergistic actions of MK-2206 and ridaforolimus (MK-8669) are due in part to limiting the mTORC2 feedback activation of Akt. Moreover, the effects of these drugs are mediated by inhibition of cellular proliferation via the retinoblastoma (Rb) pathway. Our findings suggest that dual targeting of the Akt and mTOR signaling pathways using MK-2206 and ridaforolimus (MK-8669) may be effective for treatment of CRPC, particularly for patients with deregulated Rb pathway activity. Cancer Res; 72(17); 4483\u201393. \u00a92012 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-12-0283","type":"journal-article","created":{"date-parts":[[2012,7,20]],"date-time":"2012-07-20T05:41:27Z","timestamp":1342762887000},"page":"4483-4493","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Dual Targeting of the Akt\/mTOR Signaling Pathway Inhibits Castration-Resistant Prostate Cancer in a Genetically Engineered Mouse Model"],"prefix":"10.1158","volume":"72","author":[{"given":"Nicolas","family":"Floc'h","sequence":"first","affiliation":[{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"},{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Waugh","family":"Kinkade","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"},{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"},{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Aytes","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"},{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Lefebvre","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"},{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonina","family":"Mitrofanova","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"},{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Cardiff","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Califano","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"},{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Shen","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"},{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Abate-Shen","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"},{"name":"Authors' Affiliations: Departments of 1Urology and Pathology and Cell Biology, 2Biomedical Informatics and Center for Computational Biology and Bioinformatics, and 3Medicine and Genetics & Development, 4Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York; and 5Center for Comparative Medicine and Department of Pathology, School of Medicine, University of California, Davis, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2012,8,30]]},"reference":[{"key":"2022061703511388900_bib1","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1101\/gad.1965810","article-title":"Molecular genetics of prostate cancer: new prospects for old challenges","volume":"24","author":"Shen","year":"2010","journal-title":"Genes Dev"},{"key":"2022061703511388900_bib2","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2002.10.018","article-title":"Molecular biology of the androgen receptor","volume":"20","author":"Gelmann","year":"2002","journal-title":"J Clin Oncol"},{"key":"2022061703511388900_bib3","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1200\/JCO.2005.03.4777","article-title":"Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis","volume":"23","author":"Scher","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022061703511388900_bib4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"2022061703511388900_bib5","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"2022061703511388900_bib6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3322\/canjclin.55.5.300","article-title":"Advances in prostate cancer chemotherapy: a new era begins","volume":"55","author":"Pienta","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"2022061703511388900_bib7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"2022061703511388900_bib8","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","article-title":"Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study","volume":"375","author":"Scher","year":"2010","journal-title":"Lancet"},{"key":"2022061703511388900_bib9","first-page":"3051","article-title":"Targeting AKT\/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model","volume":"118","author":"Kinkade","year":"2008","journal-title":"J Clin Invest"},{"key":"2022061703511388900_bib10","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/pros.20410","article-title":"Expression of mTOR signaling pathway markers in prostate cancer progression","volume":"66","author":"Kremer","year":"2006","journal-title":"Prostate"},{"key":"2022061703511388900_bib11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1535-7163.MCT-10-0792","article-title":"Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens","volume":"10","author":"Rivera","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2022061703511388900_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"2022061703511388900_bib13","doi-asserted-by":"crossref","first-page":"7929","DOI":"10.1158\/0008-5472.CAN-06-1637","article-title":"Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice","volume":"66","author":"Gao","year":"2006","journal-title":"Cancer Res"},{"key":"2022061703511388900_bib14","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1158\/0008-5472.CAN-04-0968","article-title":"Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells","volume":"64","author":"Uzgare","year":"2004","journal-title":"Cancer Res"},{"key":"2022061703511388900_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrclinonc.2010.21","article-title":"mTOR signaling and drug development in cancer","volume":"7","author":"Dancey","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061703511388900_bib16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1535-6108(03)00275-7","article-title":"Will mTOR inhibitors make it as cancer drugs?","volume":"4","author":"Sawyers","year":"2003","journal-title":"Cancer Cell"},{"key":"2022061703511388900_bib17","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1200\/JCO.2011.35.5263","article-title":"First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors","volume":"29","author":"Yap","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022061703511388900_bib18","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"key":"2022061703511388900_bib19","doi-asserted-by":"crossref","first-page":"17414","DOI":"10.1073\/pnas.0809136105","article-title":"Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation","volume":"105","author":"Choo","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061703511388900_bib20","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"2022061703511388900_bib21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1535-7163.MCT-08-0668","article-title":"Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K\/mTOR inhibition","volume":"8","author":"Breuleux","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"2022061703511388900_bib22","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1172\/JCI44239","article-title":"The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression","volume":"120","author":"Sharma","year":"2010","journal-title":"J Clin Invest"},{"key":"2022061703511388900_bib23","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1158\/0008-5472.CAN-06-4424","article-title":"Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells","volume":"67","author":"Sharma","year":"2007","journal-title":"Cancer Res"},{"key":"2022061703511388900_bib24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature08361","article-title":"A luminal epithelial stem cell that is a cell of origin for prostate cancer","volume":"461","author":"Wang","year":"2009","journal-title":"Nature"},{"key":"2022061703511388900_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/gene.10036","article-title":"Cre\/loxP-mediated inactivation of the murine Pten tumor suppressor gene","volume":"32","author":"Lesche","year":"2002","journal-title":"Genesis"},{"key":"2022061703511388900_bib26","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1101\/gad.13.8.966","article-title":"Roles for Nkx3.1 in prostate development and cancer","volume":"13","author":"Bhatia-Gaur","year":"1999","journal-title":"Genes Dev"},{"key":"2022061703511388900_bib27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nature03918","article-title":"Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis","volume":"436","author":"Chen","year":"2005","journal-title":"Nature"},{"key":"2022061703511388900_bib28","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061703511388900_bib29","doi-asserted-by":"crossref","first-page":"D691","DOI":"10.1093\/nar\/gkq1018","article-title":"Reactome: a database of reactions, pathways and biological processes","volume":"39","author":"Croft","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"2022061703511388900_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/nar\/27.1.29","article-title":"KEGG: Kyoto encyclopedia of genes and genomes","volume":"27","author":"Ogata","year":"1999","journal-title":"Nucleic Acids Res"},{"key":"2022061703511388900_bib31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1432-0436.2008.00292.x","article-title":"Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis","volume":"76","author":"Abate-Shen","year":"2008","journal-title":"Differentiation"},{"key":"2022061703511388900_bib32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1158\/0008-5472.CAN-10-2488","article-title":"PTEN level in tumor suppression: how much is too little?","volume":"71","author":"Carracedo","year":"2011","journal-title":"Cancer Res"},{"key":"2022061703511388900_bib33","first-page":"135","article-title":"Faithful modeling of PTEN loss driven diseases in the mouse","volume":"347","author":"Nardella","year":"2010","journal-title":"Curr Top Microbiol Immunol"},{"key":"2022061703511388900_bib34","first-page":"3886","article-title":"Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases","volume":"63","author":"Abate-Shen","year":"2003","journal-title":"Cancer Res"},{"key":"2022061703511388900_bib35","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1073\/pnas.042688999","article-title":"Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis","volume":"99","author":"Kim","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061703511388900_bib36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"2022061703511388900_bib37","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.1371\/journal.pbio.0000059","article-title":"Pten dose dictates cancer progression in the prostate","volume":"1","author":"Trotman","year":"2003","journal-title":"PLoS Biol"},{"key":"2022061703511388900_bib38","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","article-title":"Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer","volume":"4","author":"Wang","year":"2003","journal-title":"Cancer Cell"},{"key":"2022061703511388900_bib39","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ccr.2011.05.006","article-title":"Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth","volume":"19","author":"Mulholland","year":"2011","journal-title":"Cancer Cell"},{"key":"2022061703511388900_bib40","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1158\/0008-5472.CAN-07-1271","article-title":"Pten inactivation and the emergence of androgen-independent prostate cancer","volume":"67","author":"Shen","year":"2007","journal-title":"Cancer Res"},{"key":"2022061703511388900_bib41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0925-4773(00)00551-7","article-title":"Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation","volume":"101","author":"Wu","year":"2001","journal-title":"Mech Dev"},{"key":"2022061703511388900_bib42","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0002-9440(10)64228-9","article-title":"Prostatic intraepithelial neoplasia in genetically engineered mice","volume":"161","author":"Park","year":"2002","journal-title":"Am J Pathol"},{"key":"2022061703511388900_bib43","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1158\/0008-5472.CAN-10-4322","article-title":"Combination of PI3K\/mTOR inhibitors: antitumor activity and molecular correlates","volume":"71","author":"Mazzoletti","year":"2011","journal-title":"Cancer Res"},{"key":"2022061703511388900_bib44","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1535-7163.MCT-11-0606","article-title":"MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis","volume":"11","author":"Cheng","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"2022061703511388900_bib45","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","article-title":"MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo","volume":"9","author":"Hirai","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2022061703511388900_bib46","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1158\/1078-0432.CCR-08-2076","article-title":"A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies","volume":"15","author":"Hartford","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022061703511388900_bib47","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"14","author":"Rizzieri","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2022061703511388900_bib48","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","article-title":"Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies","volume":"26","author":"Mita","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022061703511388900_bib49","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/01.ju.0000141580.30910.57","article-title":"Cell lines used in prostate cancer research: a compendium of old and new lines\u2014part 1","volume":"173","author":"Sobel","year":"2005","journal-title":"J Urol"},{"key":"2022061703511388900_bib50","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccr.2006.07.003","article-title":"Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin","volume":"10","author":"Phung","year":"2006","journal-title":"Cancer Cell"},{"key":"2022061703511388900_bib51","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrc2696","article-title":"Emerging roles of E2Fs in cancer: an exit from cell cycle control","volume":"9","author":"Chen","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2022061703511388900_bib52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ccr.2008.12.017","article-title":"mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice","volume":"15","author":"Guertin","year":"2009","journal-title":"Cancer Cell"},{"key":"2022061703511388900_bib53","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1126\/science.1215135","article-title":"Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity","volume":"335","author":"Lamming","year":"2012","journal-title":"Science"},{"key":"2022061703511388900_bib54","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/nrc3057","article-title":"Pro-senescence therapy for cancer treatment","volume":"11","author":"Nardella","year":"2011","journal-title":"Nat Rev Cancer"}],"updated-by":[{"DOI":"10.1158\/0008-5472.can-23-0516","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000}}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/72\/17\/4483\/2671061\/4483.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/72\/17\/4483\/2671061\/4483.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T08:59:11Z","timestamp":1655456351000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/72\/17\/4483\/575874\/Dual-Targeting-of-the-Akt-mTOR-Signaling-Pathway"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,30]]},"references-count":54,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2012,8,30]]},"published-print":{"date-parts":[[2012,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-12-0283","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22393629.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6503826","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22393623.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22393620.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6503826.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22393629","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22393626.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22393626","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22393623","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22393632","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22393632.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22393620","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,30]]}}}